ABC Arbitrage SA Invests $8.37 Million in Takeda Pharmaceutical Co. $TAK

ABC Arbitrage SA acquired a new position in Takeda Pharmaceutical Co. (NYSE:TAK) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 571,863 shares of the company’s stock, valued at approximately $8,372,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of TAK. Smartleaf Asset Management LLC boosted its position in Takeda Pharmaceutical by 83.7% during the 3rd quarter. Smartleaf Asset Management LLC now owns 19,895 shares of the company’s stock valued at $291,000 after purchasing an additional 9,066 shares during the period. Gallacher Capital Management LLC boosted its holdings in shares of Takeda Pharmaceutical by 23.8% during the third quarter. Gallacher Capital Management LLC now owns 27,245 shares of the company’s stock valued at $399,000 after acquiring an additional 5,245 shares during the period. Savant Capital LLC grew its position in shares of Takeda Pharmaceutical by 14.7% during the third quarter. Savant Capital LLC now owns 37,640 shares of the company’s stock worth $551,000 after acquiring an additional 4,816 shares during the last quarter. Checchi Capital Advisers LLC increased its holdings in shares of Takeda Pharmaceutical by 16.9% in the 3rd quarter. Checchi Capital Advisers LLC now owns 14,190 shares of the company’s stock worth $208,000 after acquiring an additional 2,054 shares during the period. Finally, Hantz Financial Services Inc. lifted its position in Takeda Pharmaceutical by 14.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 260,174 shares of the company’s stock valued at $3,809,000 after purchasing an additional 32,933 shares during the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have commented on TAK shares. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research report on Saturday, January 31st. Weiss Ratings reissued a “hold (c-)” rating on shares of Takeda Pharmaceutical in a report on Monday, December 29th. Finally, Morgan Stanley began coverage on Takeda Pharmaceutical in a research report on Tuesday, January 13th. They issued an “overweight” rating on the stock. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold”.

Takeda Pharmaceutical Price Performance

TAK stock opened at $18.08 on Wednesday. Takeda Pharmaceutical Co. has a one year low of $12.99 and a one year high of $18.16. The firm has a 50-day moving average of $15.87 and a two-hundred day moving average of $14.97. The firm has a market capitalization of $57.53 billion, a PE ratio of 75.34 and a beta of 0.02. The company has a current ratio of 1.19, a quick ratio of 0.65 and a debt-to-equity ratio of 0.56.

Takeda Pharmaceutical (NYSE:TAK) last announced its earnings results on Thursday, January 29th. The company reported $0.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.40. The company had revenue of $6.75 billion for the quarter, compared to the consensus estimate of $7.81 billion. Takeda Pharmaceutical had a net margin of 2.58% and a return on equity of 10.60%. On average, analysts forecast that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.